Immix Biopharma, Inc. (NasdaqCM: IMMX)
Health Care · Biotechnology · US
$9.25
-2.22% today · +278.4% 1Y
Immix Biopharma, Inc. (NasdaqCM: IMMX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $784.26M and employs 21 people.
Over the last twelve months the share price has gained 278.4%, trading between 2.31 and 15.10.
Tweenvest scores Immix Biopharma, Inc. across four factors: quality 44/100, value 75/100. Its strongest factor is value.
IMMX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $784.26M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.83
- Dividend yield
- —
- Beta (5Y)
- 0.24
- 52-week high
- $15.10
- 52-week low
- $2.31
- Avg volume (3M)
- —
- Shares outstanding
- 82.90M
- Employees
- 21
- Next earnings
- —
About Immix Biopharma, Inc.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
- ISIN
- US45258H1068
- Founded
- 2012
- Listed since
- Dec 16, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| CARsgen Therapeutics Holdings LimitedSEHK: 2171 | $833.26M | HK$11.63 | -6.59% |
| ArriVent BioPharma, Inc.NasdaqGM: AVBP | $824.92M | $16.46 | -1.61% |
| Ardelyx, Inc.NasdaqGM: ARDX | $817.34M | $3.23 | -1.52% |
| Geron CorporationNasdaqGS: GERN | $787.03M | $1.22 | -0.41% |
| Achieve Life Sciences, Inc.NasdaqCM: ACHV | $762.51M | $7.06 | -4.72% |
| Annexon, Inc.NasdaqGS: ANNX | $762.11M | $3.96 | -1.49% |
| Candel Therapeutics, Inc.NasdaqGM: CADL | $760.59M | $9.78 | -1.61% |
| Verastem, Inc.NasdaqCM: VSTM | $758.92M | $8.25 | -1.55% |
Figures last refreshed Oct 11, 2026.